Moleculin Biotech Profitability Analysis

MBRX
 Stock
  

USD 1.80  0.18  11.11%   

For Moleculin Biotech profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Moleculin Biotech to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Moleculin Biotech CS utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Moleculin Biotech's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Moleculin Biotech CS over time as well as its relative position and ranking within its peers. Additionally, see Stocks Correlation.
  
Price to Sales Ratio is likely to rise to 5.88 in 2022, whereas Return on Sales is likely to drop (8.35)  in 2022. Accumulated Other Comprehensive Income is likely to rise to about 46.5 K in 2022, whereas Consolidated Income is likely to drop (16.3 M) in 2022.
Is Moleculin Biotech's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Moleculin Biotech. If investors know Moleculin will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Moleculin Biotech listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Market Capitalization
46.3 M
Return On Assets
-0.19
Return On Equity
-0.28
The market value of Moleculin Biotech is measured differently than its book value, which is the value of Moleculin that is recorded on the company's balance sheet. Investors also form their own opinion of Moleculin Biotech's value that differs from its market value or its book value, called intrinsic value, which is Moleculin Biotech's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Moleculin Biotech's market value can be influenced by many factors that don't directly affect Moleculin Biotech's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Moleculin Biotech's value and its price as these two are different measures arrived at by different means. Investors typically determine Moleculin Biotech value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Moleculin Biotech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Moleculin Biotech Total Debt vs. Beta Fundamental Analysis

Comparative valuation techniques use various fundamental indicators to help in determining Moleculin Biotech's current stock value. Our valuation model uses many indicators to compare Moleculin Biotech value to that of its competitors to determine the firm's financial worth.
Moleculin Biotech CS is considered to be number one stock in beta category among related companies. It is rated top company in total debt category among related companies making up about  70,556  of Total Debt per Beta. Moleculin Biotech Total Debt is fairly stable at the moment as compared to the past year. Moleculin Biotech reported Total Debt of 63,000 in 2021. Comparative valuation analysis is a catch-all model that can be used if you cannot value Moleculin Biotech by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Moleculin Biotech's Stock . Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Moleculin Biotech's earnings, one of the primary drivers of an investment's value.

Moleculin Total Debt vs. Beta

Beta is one of the most important measures of equity market volatility. Beta can be thought of as asset elasticity or sensitivity to market. In other words, it is a number that shows the relationship of an equity instrument to the financial market in which this instrument is traded. For example, if Beta of equity is 2, it will be expected to significantly outperform market when the market is going up and significantly underperform when the market is going down. Similarly, Beta of 1 indicates that an asset and market will generate similar returns over time.
Moleculin Biotech 
Beta 
 = 
Covariance 
Variance 
1.8
In a nutshell, Beta is a measure of individual stock risk relative to the overall volatility of the stock market. and is calculated based on very sound finance theory - Capital Assets Pricing Model (CAPM).However, since Beta is calculated based on historical price movements it may not predict how a firm's stock is going to perform in the future.
Total Debt refers to the amount of long term interest-bearing liabilities that a company carries on its balance sheet. That may include bonds sold to the public, notes written to banks or capital leases. Typically, debt can help a company magnify its earnings, but the burden of interest and principal payments will eventually prevent the firm from borrow excessively.
Moleculin Biotech 
Total Debt 
 = 
Bonds 
+  
Notes 
127 K
In most industries, total debt may also include the current portion of long-term debt. Since debt terms vary widely from one company to another, simply comparing outstanding debt obligations between different companies may not be adequate. It is usually meant to compare total debt amounts between companies that operate within the same sector.

Moleculin Total Debt vs Competition

Moleculin Biotech CS is rated top company in total debt category among related companies. Total debt of Biotechnology industry is now estimated at about 554.16 Billion. Moleculin Biotech adds roughly 127,000 in total debt claiming only tiny portion of stocks in Biotechnology industry.
Total debt  Revenue  Workforce  Valuation  Capitalization

Moleculin Biotech Profitability Projections

The most important aspect of a successful company is its ability to generate a profit. For investors in Moleculin Biotech, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Moleculin Biotech will eventually generate negative long term returns. The profitability progress is the general direction of Moleculin Biotech's change in net profit over the period of time. It can combine multiple indicators of Moleculin Biotech, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Last ReportedProjected for 2022
Accumulated Other Comprehensive Income41 K46.5 K
Consolidated Income-15.9 M-16.3 M
Net Income-15.9 M-16.3 M
Net Income Common Stock-15.9 M-16.3 M
Operating Income-23 M-23.6 M
Income Tax Expense-206.1 K-222.4 K
Net Income Per Employee-934.9 K-1 M
Moleculin Biotech, Inc., a clinical-stage pharmaceutical company, focuses on the development of drug candidates for the treatment of highly resistant tumors and viruses. Moleculin Biotech, Inc. was incorporated in 2015 and is headquartered in Houston, Texas. Moleculin Biotech operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 13 people.

Moleculin Profitability Driver Comparison

Profitability drivers are factors that can directly affect your investment outlook on Moleculin Biotech. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Moleculin Biotech position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Moleculin Biotech's important profitability drivers and their relationship over time.

Moleculin Biotech Profitability Trends

Moleculin Biotech profitability trend refers to the progression of profit or loss within a business. An upward trend means that Moleculin Biotech's profit has generally increased over time, and a downward profitability trend means profits are declining. Recognizing problems early in profitability trends allows investors to address revenue and cost issues in advance. Investors and analysts usually monitor three types of profitability trends: gross, operating, and net. Gross profit is the difference between revenue and costs of goods sold. Operating profit is Moleculin Biotech's gross profit minus its overhead. After you account for other unusual revenue, expenses, and costs, you get net profit. Gross profit trends are often a good indicator of future profitability. If you have high gross profit margins, you have a better chance to cover overhead and make money.

Moleculin Biotech Profitability Drivers Correlations

One of the toughest challenges investors face today is learning how to quickly synthesize and read into endless financial statements and information provided by the company, SEC reporting, and various external parties. Understanding the correlation between Moleculin Biotech different financial indicators related to revenue and profit generation helps investors identify and prioritize their investing strategies towards Moleculin Biotech in a much-optimized way. Analyzing correlations between profit drivers that are directly associated with dollar figures is the most effective way to break down Moleculin Biotech's future profitability.

Use Moleculin Biotech in pair-trading

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Moleculin Biotech position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Moleculin Biotech will appreciate offsetting losses from the drop in the long position's value.

Moleculin Biotech Pair Trading

Moleculin Biotech CS Pair Trading Analysis

The ability to find closely correlated positions to Moleculin Biotech could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Moleculin Biotech when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Moleculin Biotech - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Moleculin Biotech CS to buy it.
The correlation of Moleculin Biotech is a statistical measure of how it moves in relation to other equities. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Moleculin Biotech moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Moleculin Biotech moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Moleculin Biotech can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Use Investing Themes to Complement your Moleculin Biotech position

In addition to having Moleculin Biotech in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Construction Materials Thematic Idea Now

Construction Materials
Construction Materials Theme
Fama and French investing themes focus on testing asset pricing under different economic assumptions. The Construction Materials theme has 61 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Construction Materials Theme or any other thematic opportunities.
View All  Next Launch
Additionally, see Stocks Correlation. Note that the Moleculin Biotech information on this page should be used as a complementary analysis to other Moleculin Biotech's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Shere Portfolio module to track or share privately all of your investments from the convenience of any device.

Complementary Tools for Moleculin Stock analysis

When running Moleculin Biotech price analysis, check to measure Moleculin Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Moleculin Biotech is operating at the current time. Most of Moleculin Biotech's value examination focuses on studying past and present price action to predict the probability of Moleculin Biotech's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Moleculin Biotech's price. Additionally, you may evaluate how the addition of Moleculin Biotech to your portfolios can decrease your overall portfolio volatility.
Crypto Correlations
Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
Go
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Go
Correlation Analysis
Reduce portfolio risk simply by holding instruments which are not perfectly correlated
Go
Equity Search
Search for actively traded equities including funds and ETFs from over 30 global markets
Go
Global Correlations
Find global opportunities by holding instruments from different markets
Go
ETF Directory
Find actively traded Exchange Traded Funds (ETF) from around the world
Go
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
Go
Portfolio Center
All portfolio management and optimization tools to improve performance of your portfolios
Go
Analyst Recommendations
Analyst recommendations and target price estimates broken down by several categories
Go
Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
Go
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
Go
To fully project Moleculin Biotech's future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Moleculin Biotech at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Moleculin Biotech's income statement, its balance sheet, and the statement of cash flows.
Potential Moleculin Biotech investors and stakeholders can use historical trends found within financial statements to determine how well the company is positioned for the future. Although Moleculin Biotech investors may work on each financial statement separately, they are all related. The changes in Moleculin Biotech's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Moleculin Biotech's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.